Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADC-1013 in advanced solid tumors
NCT02379741Phase 1Completed
- Sponsor
- Alligator Bioscience AB
- Start
- Apr 2015
- Primary completion
- Mar 2017
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of mitazalimab in solid tumor (2 arms), sponsored by Alligator Bioscience AB. Primary endpoint: Safety and tolerability of increasing doses of ADC-1013. Started Apr 2015; status: completed.
02
Drugs
mitazalimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02379741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02379741.